W1283 Infliximab Monotherapy vs. Combined Infliximab-Immunomodulator Therapy in Ulcerative Colitis

Yelena Zadvornova; Ashwin N. Ananthakrishnan; Dan Joseph Stein; Susan Skaros; Kathryn Johnson; Amar S. Naik; Lilani P. Perera; Mazen Issa

doi:10.1016/s0016-5085(10)63174-5

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2014

Predictors of Infliximab Failure in Ulcerative Colitis

Dan Joseph Stein, Brian W. Behm

Article2022

Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses

Shunsuke Fujita, Hajime Honjo, Ryutaro Takada, Akane Hara, Yasuhiro Masuta, Yasuo Otsuka, Kohei Handa, Kosuke Minaga, Shigeyoshi Tsuji, Masatoshi Kudo, Tomohiro Watanabe

Article2017

Accelerated Dosing of Infliximab Is Not Associated With Improved Colectomy Rates in Hospitalized Severe Ulcerative Colitis Patients

Nichole Sly, Shannon L. Werner, Renee D. Pitt, Ruta Bajorunaite, Lisa Rein, Dan Joseph Stein

Article2018

Baseline Ulcerative Colitis Endoscopic Index of Severity and Endoscopic Mayo Score Perform Similarly Predicting Response to Medical Therapy in Patients with Ulcerative Colitis

Hasan Bader, Lawrence Seymour, John Grady, Dan Joseph Stein, Andrés Yarur

Article2024

Necrotizing Fasciitis of the Serratus Anterior in a Patient Treated With Infliximab and Prednisolone for Ulcerative Colitis and Rheumatoid Arthritis

Natsuki Okai, Yasuo Otsuka, Sho Masaki, Masatoshi Kudo, Tomohiro Watanabe